Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.39
07/11/2023 12:00
Nov 07 (Reuters) - Fulcrum Therapeutics Q3 operating expenses USD 28.199 million. * Q3 operating income USD -27.44 million * Q3 net income USD -24.017 million * Q3 collaboration revenue USD 759 thousand
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program